In vivo pharmacological characterisation of bilastine, a potent and selective histamine H1 receptor antagonist.
about
Bilastine vs. hydroxyzine: occupation of brain histamine H1 -receptors evaluated by positron emission tomography in healthy volunteersTreatment of allergic rhinitis and urticaria: a review of the newest antihistamine drug bilastineAcute and subchronic effects of bilastine (20 and 40 mg) and hydroxyzine (50 mg) on actual driving performance in healthy volunteers.An overview of the novel H1-antihistamine bilastine in allergic rhinitis and urticaria.Bilastine: in allergic rhinitis and urticaria.Critical appraisal of bilastine for the treatment of allergic rhinoconjunctivitis and urticariaH1 antihistamines: current status and future directions.Evaluation of the single-dose pharmacokinetics of bilastine in subjects with various degrees of renal insufficiency.The role and choice criteria of antihistamines in allergy management - expert opinion.Safety and efficacy of bilastine: a new H(1)-antihistamine for the treatment of allergic rhinoconjunctivitis and urticaria.Bilastine for the treatment of urticaria.New therapies for allergic rhinitis.Bilastine: new insight into antihistamine treatment.Bilastine: a new H1 -antihistamine with an optimal profile for updosing in urticaria.Bilastine: a new nonsedating oral H1 antihistamine for treatment of allergic rhinoconjunctivitis and urticaria.Oral availability of bilastine.Quality of life in patients with allergic rhinitis: a clinical trial comparing the use of bilastine versus loratadine.Bilastine in allergic rhinoconjunctivitis and urticaria
P2860
Q24563637-883786E6-CA7B-4418-8E66-34BA99B5759DQ26750723-C6175E0C-B1D1-4149-B9FC-7A166D69B68BQ34139004-F1723285-C9BF-4C1B-80DB-A9C8568592D9Q34238984-8B661253-BB65-4C0E-A255-9E564717408DQ34639105-385855BE-3445-413C-B315-BFD00E5E132DQ36833151-798639D7-227F-4986-98D5-CB690D2BD195Q36834344-C20609B4-1FF0-40BD-9F76-E60809B2AFD8Q37115078-46335C2D-D77E-4669-BC38-403AE5169BF4Q37531868-4C381181-52A6-4E3D-B03B-F66BF08E4ED2Q37914886-74DA3392-1F0F-4005-A590-274B11D41EFAQ38107004-FA3D78E5-3EC7-4A06-9CE6-52066223053EQ38185937-E0426B95-3382-4D2B-AA48-E2D2440E66A1Q38423124-D78CE5CC-3A13-4FCE-B7A0-13C88FBA3215Q39280604-5339905A-22FE-45C3-AE6D-D7246B959841Q42052228-2D998968-D8E7-4A0A-9C31-8A24053750B4Q42693919-EFED222F-5F43-4942-8D0A-E329C811DF30Q47705701-76248812-D31C-4761-9B64-35F5E0B3E301Q57479825-EFC6F829-050E-4F53-85B6-0BDAB53D1C48
P2860
In vivo pharmacological characterisation of bilastine, a potent and selective histamine H1 receptor antagonist.
description
2006 nî lūn-bûn
@nan
2006 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
In vivo pharmacological charac ...... tamine H1 receptor antagonist.
@ast
In vivo pharmacological charac ...... tamine H1 receptor antagonist.
@en
type
label
In vivo pharmacological charac ...... tamine H1 receptor antagonist.
@ast
In vivo pharmacological charac ...... tamine H1 receptor antagonist.
@en
prefLabel
In vivo pharmacological charac ...... tamine H1 receptor antagonist.
@ast
In vivo pharmacological charac ...... tamine H1 receptor antagonist.
@en
P2093
P1433
P1476
In vivo pharmacological charac ...... tamine H1 receptor antagonist.
@en
P2093
Agustín Berisa
Ana Innerárity
Aurelio Orjales
Luis Labeaga
Reyes Corcóstegui
P304
P356
10.2165/00126839-200607040-00002
P577
2006-01-01T00:00:00Z